Today, shares of Zydus Lifesciences gained over 2% and hit a fresh new 52-week high of Rs 764.40 per share from its previous closing of Rs 748.85. The shares of the company saw a spurt in volume by more than 2 times on BSE.
In a significant stride towards enhancing healthcare accessibility and affordability, Zydus Lifesciences Ltd has introduced Relugolix under the brand name, Rexigo, in India. This groundbreaking oral therapy marks a pivotal moment in the management of advanced prostate cancer, offering patients a more convenient and cost-effective treatment option. With its unique formulation and better cardiovascular safety profile, Rexigo promises to redefine the landscape of prostate cancer therapy in the country.
Prostate cancer stands as one of the most prevalent cancers affecting men globally, and India is no exception. According to the National Cancer Registry Program of India, over 43,000 cases were reported in 2022 alone. Testosterone, a hormone belonging to the ‘Androgens’ family, plays a pivotal role in driving the growth of prostate cancer cells. Consequently, one of the primary strategies in managing this disease is Androgen Deprivation Therapy (ADT), aimed at suppressing testosterone levels. Traditionally, ADT has been administered through injections, requiring frequent visits to healthcare facilities and supervision by caregivers.
However, the advent of Rexigo heralds a new era in prostate cancer treatment. As the first generic, oral, once-a-day pill for testosterone suppression, Rexigo eliminates the need for injections, offering patients unparalleled convenience and autonomy in managing their condition. This shift from injections to oral medication represents a significant advancement, simplifying treatment regimens and improving patient adherence.
Read: Life Insurance Payouts: Fewer Death Claims, More Cash-Outs?
Moreover, Rexigo boasts a superior cardiovascular safety profile, particularly beneficial for elderly patients with comorbidities. By mitigating the risks associated with traditional injectable therapies, Rexigo provides a safer alternative for a broader demographic of patients, ensuring their overall well-being and quality of life.
The introduction of Rexigo also addresses long-standing issues of access and affordability in prostate cancer therapy. Despite being available in developed countries for the past four years, Relugolix remained inaccessible to patients in India. Zydus Lifesciences Ltd.’s initiative not only brings this critical therapy within reach but also significantly reduces its cost. Priced at Rs 6,995 per month, Rexigo is offered at a 50% discount compared to existing injectable options, making it more accessible to a larger segment of the population.
This milestone achievement underscores Zydus Lifesciences Ltd.’s commitment to innovation-driven healthcare and patient-centric solutions. By manufacturing Rexigo at its own premises, the company ensures stringent quality control measures and streamlined distribution channels, guaranteeing consistent availability and reliability of the medication.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
